Press release
Global Spasticity Treatment Landscape Set for Transformation: DelveInsight Unveils Insights into 12+ Pipeline Therapies
Spasticity Pipeline
Stay informed with the latest developments! Access DelveInsight's comprehensive Spasticity Pipeline Report to review emerging therapies, leading companies, and the evolving treatment landscape. Explore the report here - Spasticity Pipeline Outlook: https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Insights from the Spasticity Pipeline Report
• July 2025: Celgene launched a Phase II study evaluating the safety, efficacy, and tolerability of three oral doses of BMS-986368―a dual FAAH/MAGL inhibitor―for managing Spasticity in patients with Multiple Sclerosis (BALANCE-MSS-1).
• June 2025: Ipsen initiated a study assessing escalating doses of IPN10200 to determine its pharmacodynamic profile and identify the optimal dose with the best balance of efficacy and safety for treating adult upper limb spasticity.
• The report outlines a dynamic pipeline with 10+ active companies developing 12+ novel therapeutic candidates targeting Spasticity.
• Major industry players include Elpida Therapeutics SPC, Saol Therapeutics, Revance Therapeutics Inc., BlackfinBio Ltd., Ipsen, Motor Pharma, Lundbeck A/S, and others.
• Notable emerging candidates include IPN10200, SL-1002, Botulinum toxin type A, SPARC0921, Tizanidine, Moxifloxacin, and Meditoxin® administered under ultrasonography guidance.
Discover advancements reshaping Spasticity care. Access the full clinical pipeline and study insights: https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Spasticity Overview
Spasticity is a motor disorder characterized by increased muscle tone, stiffness, and involuntary spasms resulting from disrupted communication between the brain, spinal cord, and muscles. It commonly arises from neurological conditions such as stroke, multiple sclerosis, cerebral palsy, traumatic brain injury, and spinal cord injury. This abnormal muscle tightness can interfere with mobility, daily activities, and overall quality of life. Severity varies widely, ranging from mild tightness to painful, uncontrollable contractions. Management typically involves physical therapy, oral medications, botulinum toxin injections, or advanced interventions such as intrathecal therapies. Ongoing research aims to develop more targeted and long-lasting treatment options.
Emerging Spasticity Drug Profiles
MELPIDA - Elpida Therapeutics SPC
Elpida Therapeutics SPC, a Social Purpose Corporation, focuses on gene therapies for ultra-rare pediatric disorders. Its flagship candidate, Melpida, is an AAV9-mediated gene therapy engineered to deliver a functional AP4M1 gene for treating SPG50 via intrathecal administration. Having completed Phase I/II studies, it has received FDA clearance to progress to a Phase III trial involving eight children beginning August 2024. Beyond SPG50, Elpida is advancing gene therapy programs for conditions such as CMT4J. Melpida is currently in Phase III development.
SL-1002 - Saol Therapeutics
SL-1002 is a proprietary chemoneurolytic injection under evaluation for managing limb spasticity and knee osteoarthritis-related pain in adults. The therapy is currently in Phase II clinical development for Spasticity.
IPN-10200 - Ipsen
IPN-10200 is a next-generation, extended-duration botulinum neurotoxin type A (mrBoNT/A) developed to offer longer-lasting therapeutic effects. Administered intramuscularly, it is in Phase I/II clinical trials for both aesthetic indications (e.g., glabellar and forehead lines) and adult upper limb spasticity due to stroke or traumatic brain injury. Ongoing trials aim to determine its safety profile, efficacy, and optimal dosing regimen.
What the Spasticity Pipeline Report Covers
• Comprehensive profiles of companies developing Spasticity therapies and the total number of programs under each.
• Classification of therapeutic candidates by development stage: early-, mid-, and late-stage.
• Overview of active and inactive (paused or discontinued) development programs.
• Assessment of therapies by development phase, route of administration, mechanism of action, molecular type, and monotherapy vs. combination therapy.
• Detailed insights into ongoing collaborations, licensing agreements, and financial activities influencing pipeline progress.
Gain deeper visibility into groundbreaking programs advancing Spasticity treatment.
Explore the full report - Spasticity Unmet Needs: https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Leading Companies in the Spasticity Pipeline
Elpida Therapeutics SPC | Saol Therapeutics | Revance Therapeutics Inc. | BlackfinBio Ltd | Ipsen | Motor Pharma | Lundbeck A/S | Others
Spasticity Pipeline Segmentation by Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular
Spasticity Pipeline Segmentation by Molecule Type
• Monoclonal antibody
• Small molecule
• Peptide
Access strategic insights into emerging therapies and key developmental milestones. Explore Spasticity Market Drivers, Barriers, and Forecasts:
https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Spasticity Pipeline Report
• Geographical Coverage: Global
• Key Companies: Elpida Therapeutics SPC, Saol Therapeutics, Revance Therapeutics Inc., BlackfinBio Ltd, Ipsen, Motor Pharma, Lundbeck A/S, and others
• Notable Pipeline Candidates: IPN10200, SL-1002, Botulinum toxin type A, SPARC0921, Tizanidine, Moxifloxacin, Meditoxin® (ultrasound-guided), etc.
• Therapeutic Assessment: Mono, Combination, and Hybrid regimens
• Development Stages: Discovery, Preclinical, Phase I, Phase II, Phase III
Identify the key innovators and leading programs in Spasticity drug development.
Explore the emerging drugs and major companies shaping the future:
https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Spasticity Treatment Landscape Set for Transformation: DelveInsight Unveils Insights into 12+ Pipeline Therapies here
News-ID: 4276753 • Views: …
More Releases from DelveInsight Business Research
Global Clostridium Difficile Infections Pipeline Expands With 20+ Companies Adva …
DelveInsight's report, "Clostridium Difficile Infections Pipeline Insight, 2025," delivers an extensive overview of the current clinical development status and future growth opportunities within the CDI market.
The report offers a comprehensive commercial and clinical analysis of pipeline therapies, spanning from preclinical stages to marketed products. It includes detailed drug profiles covering mechanisms of action, clinical data, regulatory milestones, and product development updates such as technological innovations, collaborations, mergers and acquisitions, funding…
Global Urticaria Pipeline Expands With 20+ Companies Advancing 25+ Therapies, Re …
DelveInsight's "Urticaria Pipeline Insight, 2025" report provides an in-depth overview of the current landscape of clinical development and future growth potential within the Urticaria market.
The report delivers a comprehensive commercial and clinical analysis of pipeline therapies, spanning preclinical research to marketed products. It offers detailed drug profiles covering mechanisms of action, clinical study updates, regulatory milestones, and product development activities, including technology platforms, partnerships, collaborations, acquisitions, funding, designations, and other…
Global Neurofibromatosis Type 2 Pipeline Expands With 5+ Companies Advancing 5+ …
According to DelveInsight's analysis, the global Neurofibromatosis Type 2 (NF2) pipeline consists of more than five leading companies actively advancing over five therapeutic candidates. The assessment includes a comprehensive review of ongoing clinical trials, therapy mechanisms, routes of administration, and recent development activities.
DelveInsight's "Neurofibromatosis Type 2 Pipeline Insight, 2025" report delivers an extensive overview of the current clinical landscape and future growth potential across the Neurofibromatosis Type 2 market. The…
CDMO Market Poised for 7.25% CAGR Growth by 2032, According to DelveInsight
DelveInsight's report, "Contract Development Manufacturing Organization Market Insights, Competitive Landscape and Market Forecast-2032," offers detailed insights into current and future market trends, technological advancements, key challenges, growth drivers, and barriers. It also highlights major emerging offerings and profiles key CDMO companies shaping the market.
DelveInsight's analysis indicates that the Contract Development and Manufacturing Organization (CDMO) market is expanding rapidly, driven by the rising burden of chronic diseases such as cancer, cardiovascular…
More Releases for Spasticity
Spasticity Market 2025-2034 Business Outlook, Critical Insight and Growth
Introduction
Spasticity is a motor disorder characterized by involuntary muscle stiffness, spasms, and exaggerated reflexes caused by damage to the central nervous system (CNS). It frequently occurs as a complication of stroke, multiple sclerosis (MS), cerebral palsy, traumatic brain or spinal cord injury, and other neurological conditions. Spasticity can severely impact mobility, daily functioning, and quality of life, making it a significant healthcare burden worldwide.
Treatment approaches combine pharmacological agents, intrathecal therapies,…
Muscle Spasticity Market Emerging Trends and Growth Prospects 2034
Introduction
Muscle spasticity is a condition characterized by involuntary muscle stiffness, spasms, and increased tone, often resulting from neurological disorders such as multiple sclerosis, cerebral palsy, stroke, or traumatic brain and spinal cord injuries. It significantly impacts mobility and quality of life, making effective management essential. With the rising incidence of neurological diseases and advancements in physiotherapy, drug therapies, and medical devices, the global muscle spasticity market is witnessing steady expansion.
According…
Spasticity Drugs Market Segments, Growth and Trends by Forecast by 2031
The report is segmented By Drug Type (Baclofen, Botulinum Toxin, Diazepam, Tizanidine, Dantrolene Sodium, and Others), Route of Administration (Oral, Intramuscular, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Get Sample Copy -https://www.theinsightpartners.com/sample/TIPRE00040811/?utm_source=OpenPR&utm_medium=10831
Major Companies operating in the Spasticity Drugs Market are:
Ipsen Pharma
Allergan
Acorda Therapeutics,…
Spasticity Drugs Top Companies Regional and Data Analysis to 2031
The Spasticity Drugs Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits.
Download PDF Brochure at: https://www.theinsightpartners.com/sample/TIPRE00040811/?utm_source=OpenPR&utm_medium=10129
Major Companies operating in the Spasticity Drugs Market are:
• Ipsen Pharma
• Allergan
• Acorda Therapeutics, Inc.
• Merz Pharma
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Beximco Pharmaceuticals Ltd.
• Johnson & Johnson Private Limited
• Zydus Cadila
Contact Us:
If you have any queries about this report or if…
Spasticity Treatment Market Expecting Huge Demand in Upcoming Years
The Global Spasticity Treatment Market size is estimated at $5.7 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 4.9% to reach $8.8 Billion by 2034. Download now
The latest study released on the Global Spasticity Treatment Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Spasticity Treatment market study covers significant research data and proofs to be a handy resource…
Muscle Spasticity Market Growth, Research Report, Analysis & Trends 2023-2033
Muscle Spasticity Market Report Overview:
Report Attribute Details
Base Year 2022
Forecast Years …
